NeuroSense Therapeutics Ltd. - Ordinary Shares - Nakit Akışı (NASDAQ:NRSN)

Financials

İşletme faaliyetlerinden elde edilen nakit 1.54 M7.59 M8.45 M-10.13 M-7.67 M — Yatırım faaliyetlerinden elde edilen nakit 17 K3.54 M3.65 M1 000-8 000 — Finansman faaliyetlerinden elde edilen nakit 11.9 M3.69 M3.9 M10.91 M4.43 M — Serbest nakit akışı 1.54 M7.59 M8.45 M-10.14 M-7.68 M —

Haberler

Roth/MKM, ALS ilacı potansiyeli ile NeuroSense hissesine al önerisi verdi

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential

Neurosense Therapeutics hisseleri PrimeC için Avustralya patentini aldıktan sonra yükseldi

Neurosense Therapeutics stock rises after securing Australian patent for PrimeC

Neurosense hisseleri, Alzheimer ilacının olumlu güvenlik profili göstermesiyle yükseldi

Neurosense stock rises as Alzheimer’s drug shows favorable safety profile

NRSN stock touches 52-week high at $1.65 amid robust gains

NRSN stock touches 52-week high at $1.52 amid growth optimism

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - NeuroSense Therapeutics (NASDAQ:NRSN)

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics (NASDAQ:NRSN), Primis Finl (NASDAQ:FRST)